Acromegaly Is Poor Setting For Symptom Claim, FDA Somatuline Review Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ipsen could not support extension of acromegaly therapy indications past biochemical endpoints to include clinical symptom claims, according to FDA’s review of the European firm’s Somatuline Depot (lanreotide prolonged-release injection).